Exelixis
EXEL
#1325
Rank
HK$133.09 B
Marketcap
HK$545.45
Share price
1.25%
Change (1 day)
69.38%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): HK$2.22

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$27.13. In 2022 the company made an earnings per share (EPS) of HK$4.47 a decrease over its 2021 EPS that were of HK$5.80.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)HK$2.22-50.24%
2022HK$4.47-22.97%
2021HK$5.80100%
2020HK$2.90-65.09%
2019HK$8.31-53.91%
2018HK$18.03333.96%
2017HK$4.16-260.61%
2016-HK$2.59-58.75%
2015-HK$6.27-42.45%
2014-HK$10.905.3%
2013-HK$10.3543.48%
2012-HK$7.21-264.29%
2011HK$4.39-165.88%
2010-HK$6.66-32.54%
2009-HK$9.88-17.65%
2008-HK$12.0075.86%
2007-HK$6.82-25.64%
2006-HK$9.178.33%
2005-HK$8.47-42.86%
2004-HK$14.8230.34%
2003-HK$11.37-5.23%
2002-HK$12.00-0.65%
2001-HK$12.07-51.88%
2000-HK$25.09

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
HK$52.41 93.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$5.96-78.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$127.17 368.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$14.92-45.00%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$7.78-71.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$35.44 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$22.56-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-HK$111.49-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-HK$6.59-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA